Clinical

Little data exist on the effectiveness of dupilumab in Black and Hispanic children, even though severe asthma disproportionately affects these populations.

Undifferentiated connective tissue disease (UCTD) is challenging to define but is a distinct clinical entity from connective tissue diseases (CTD).

Sacubitril/valsartan reduced mean pulmonary artery pressure (mPAP) and improved lung congestion, functional capacity, and quality of life in a subset of patients with heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH) using a remote monitoring platform.

The label expansion means risdiplam is approved for spinal muscular atrophy for all ages.

Panelists share their final insights on improving the trajectory for women’s health care.

This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics.

This expert panel considers an increasing collaborative effort between payers, patients, and providers for patient-centered care.

Findings from the phase 3 SHINE trial could make ibrutinib the standard treatment option for older patients with mantle cell lymphoma (MCL), who often cannot tolerate chemotherapy or transplant strategies, according to study authors.

Forty-two percent of patients in the cohort had an adverse pregnancy outcome.

Encouraging outcomes in recent studies have the authors of a recent review calling for more research on the effect of cannabinoids on sleep disorders.

The analysis suggests the marker could be used to screen patients for potential immunotherapy.

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version.

A payer discusses medical exceptions processes and triggers for a class review for drugs in women’s health, along with wraparound programs for uterine fibroids and endometriosis.

A medical professional explains the many facets of the prior authorizations process for drugs in women’s health.

Ryan Haumschild, PharmD, MBA, MS, provides background on the Affordable Care Act (ACA) within the scope of women’s health, including specific mandates on contraceptives.

This new study, from Taiwan, investigated how menopause affects ventricular structure and function and its possible impact on heart failure among women.

Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.

This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.

Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.

A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.

Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.

The findings from the study indicate that higher genetic risk score for Alzheimer disease (AD) are associated with cognitive declines in patients with Parkinson disease (PD), while higher genetic risk scores for PD signify an increased risk of PD, albeit with slower clinical progression after diagnosis.

Results of a randomized controlled trial found supplementation with vitamin D among those at risk for type 2 diabetes (T2D) did not prevent onset of the disease.

Angel Qin, MD, clinical assistant professor of medicine at the University of Michigan, discusses the need for more clinical trials in small cell lung cancer and for more patients to qualify for trials.

Surveys of patients and oncologists found discrepancies between patient experiences and oncologist perceptions of those experiences during a nonmedical switch to trastuzumab biosimilars.